Perampanel (INN/USAN, prodajno ime Fycompa) antiepileptički je lek koji deluje kao selektivni nekompetitivni antagonist AMPA receptora, jednog od glavnih tipova jonotropnih glutamatnih receptora.[1][2][3][4][5]
- ^ Rogawski, M. A. (2011). „Revisiting AMPA Receptors as an Antiepileptic Drug Target”. Epilepsy Currents. 11 (2): 56—63. PMC 3117497 . PMID 21686307. doi:10.5698/1535-7511-11.2.56.
- ^ Rogawski MA, Hanada T. (2013). „Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist”. Acta Neurol Scand. 127 (Suppl. 197): 19—24. doi:10.1111/ane.12100.
- ^ Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y: Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011 Jul;52(7):1331-40. doi: 10.1111/j.1528-1167.2011.03109.x. Epub 2011 Jun 2. PMID 21635236
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди